Leading AI researchers from OpenAI, Anthropic, and Google DeepMind have issued urgent warnings about the catastrophic risks posed by advanced AI technologies. Experts like Yoshua Bengio, Geoffrey Hinton, and Aidan Gomez highlight dangers including AI's potential to strategize harmfully, create biological and cyber viruses, and exploit vulnerabilities at scale. Their calls for regulatory oversight come amid heated political debate in the US, with some lawmakers pushing for AI regulation while former President Trump opposes it. The experts emphasize the need for careful monitoring and governance to prevent AI from becoming uncontrollable and dangerous.
AI risks and warnings from leading researchers come as a backdrop to market movements in the technology sector. For readers following technology stocks, here is Pluang's market snapshot as of Sep 15, 2026 20:11 WIB: out of 150 priced US technology stocks, 52 rose and 91 fell. Notable price changes include SAP SE at USD 213.29 with a -2.29% change, Cloudflare Inc at USD 323.00 down by -2.26%, and Wipro Limited at USD 1.74 down by -2.25%.
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
Tyson Foods is experiencing significant losses in its beef segment, with a projected loss of $500 million to $650 million for the fiscal year, causing its stock to decline. However, the company's dividend remains secure because its chicken and prepar...
Amazon is investing hundreds of billions in data centers, servers, and chips, aiming for long-term returns as these assets generate revenue over decades. AWS revenue grew 37% in Q2 with a strong operating margin, and the company has a $496 billion ba...
Northern Graphite Corporation has engaged German advisory firm DGWA to enhance its investor relations and visibility in Europe, especially in German-speaking regions. The partnership aims to attract strategic investors, institutional funds, and indus...
TuHURA Biosciences announced the issuance of a U.S. patent for their Delta Opioid Receptor (DOR) antagonist technology, which reprograms immunosuppressive cells to enhance cancer immunotherapy. This patent covers the use of DOR antagonists in combina...
